Cannabidiol modulation of hippocampal glutamate in early psychosis

Abstract

Background:

Emerging evidence supports the antipsychotic effect of cannabidiol, a non-intoxicating component of cannabis, in people with psychosis. Preclinical findings suggest that this antipsychotic effect may be related to cannabidiol modulating glutamatergic signalling in the brain.

Aim:

The purpose of this study was to investigate the effects of cannabidiol on the neurochemical mechanisms underlying psychosis.

Methods:

We investigated the effects of a single oral dose of cannabidiol (600 mg) in patients with psychosis, using a double-blind, randomised, placebo-controlled, repeated-measures, within-subject cross-over design. After drug administration, 13 patients were scanned using proton magnetic resonance spectroscopy to measure left hippocampal glutamate levels. Symptom severity was rated using the Positive and Negative Syndrome Scale 60 min before drug administration (pre-scan), and 270 min after drug administration (post-scan). Effects of cannabidiol on hippocampal glutamate levels, symptom severity, and correlations between hippocampal glutamate and symptoms were investigated.

Results:

Compared to placebo, there was a significant increase in hippocampal glutamate (p=0.035), and a significantly greater decrease in symptom severity (p=0.032) in the psychosis patients under cannabidiol treatment. There was also a significant negative relationship between post-treatment total Positive and Negative Syndrome Scale score and hippocampal glutamate (p=0.047), when baseline Positive and Negative Syndrome Scale score, treatment (cannabidiol vs placebo), and interaction between treatment and glutamate levels were controlled for.

Conclusions:

These findings may suggest a link between the increase in glutamate levels and concomitant decrease in symptom severity under cannabidiol treatment observed in psychosis patients. Furthermore, the findings provide novel insight into the potential neurochemical mechanisms underlying the antipsychotic effects of cannabidiol.

Keywords

Cannabidiol psychosis glutamate proton magnetic resonance spectroscopy hippocampus schizophrenia

Introduction

Δ9-Tetrahydrocannabinol (Δ9-THC), the primary psychoactive substance in cannabis, is a well-replicated risk factor for the onset and relapse of psychosis (Moore et al., 2007; Schoeler et al., 2016a, 2016b). Acute exposure has been shown to induce psychotic symptoms and alter activity in brain regions underlying psychotic symptoms in healthy individuals (Bhattacharyya et al., 2009, 2010; Bossong et al., 2012; D’Souza et al., 2004; Englund et al., 2013; Ranganathan et al., 2017; Schoeler and Bhattacharyya, 2013; Winton-Brown et al., 2011) and exacerbate symptoms in people with pre-existing psychosis (D’Souza et al., 2005). In contrast, cannabidiol (CBD), a non-intoxicating component of cannabis, has been shown to counteract these effects, displaying an antipsychotic effect as well as neural effects opposing that of Δ9-THC (Bhattacharyya et al., 2010, 2012a, 2015; Englund et al., 2013; Morgan et al., 2010; Winton-Brown et al., 2011). Further evidence regarding the antipsychotic efficacy of cannabidiol has emerged from independent clinical trials (Leweke et al., 2012; McGuire et al., 2017), though results have not always been consistent (Boggs et al., 2018). However, how CBD might exert its antipsychotic effect remains unclear. While current drugs for psychosis typically target the dopaminergic neurotransmitter system, it appears increasingly likely that CBD may directly or indirectly affect multiple distinct modes of neural signalling, including both glutamate and dopamine (Campos et al., 2016). Indeed, preclinical evidence suggests that CBD may attenuate the molecular changes induced by the antagonism of N-methyl-D-aspartate (NMDA) glutamate receptors (Gomes et al., 2014; Long et al., 2006; Moreira and Guimarães, 2005). This is consistent with evidence that CBD may increase glutamate levels in the ventromedial prefrontal cortex both acutely and following chronic treatment in freely moving animal models of depression, as well as acutely in healthy animals (Linge et al., 2016). However, an opposite effect on glutamate release, as measured in hippocampal synaptosomes, has also been reported in a cocaine-induced preclinical model of seizure (Gobira et al., 2015). A recent human study suggests that a single dose of CBD may increase Glx (the combination of glutamate and the glutamate metabolite glutamine) levels in the basal ganglia and decrease it in the dorsomedial prefrontal cortex in a group of healthy individuals (n=14) and individuals with autism spectrum disorder (n=9) (Pretzsch et al., 2019). However, whether CBD can modulate brain glutamate levels in patients with psychosis remains unclear.

Although a number of studies have investigated levels of glutamate and related metabolites as measured using proton magnetic resonance spectroscopy (¹H-MRS) in patients with established psychosis, the results have been somewhat inconsistent (as demonstrated by three independent meta-analyses (Iwata et al., 2018; Marsman et al., 2013; Merritt et al., 2016). Indeed, there is evidence to suggest that these inconsistencies may be due to the stage of illness of the patient. Specifically, studies have reported levels of glutamate, glutamine, and/or Glx to be higher in the earlier stages of illness and lower in more chronic patients (Brandt et al., 2016; Duarte and Xin, 2019; Hashimoto et al., 2005; Ohrmann et al., 2005; Tayoshi et al., 2009; Tibbo et al., 2004). Some also suggesting a general decline with increasing age amongst patients but not controls (Brandt et al., 2016; Schwerk et al., 2014). This is also consistent with recent multimodal evidence suggesting an inverse relationship between cortical glutamate levels, and both striatal dopamine, and positive psychotic symptoms, in first episode psychosis patients (Jauhar et al., 2018).

We have recently shown that CBD may partially normalise activation in the prefrontal cortex (PFC) and medial temporal lobe (MTL) during a verbal memory task, as well as resting state functional connectivity between the hippocampus and striatum, in people in the early stages of psychosis (O’Neill et al., 2020). This is supported by our previous finding of a CBD-induced partial normalization of activation in the MTL and striatum during the same verbal memory task in people at clinical high-risk of psychosis (Bhattacharyya et al., 2018). However, to the best of our knowledge, no study has as yet investigated the effect of CBD on brain glutamate levels in patients with psychosis as a potential mechanism underlying its antipsychotic effects. Therefore, the main aim of this study was to investigate the acute effect of a single dose of CBD on left hippocampal glutamate levels and symptoms in people with established psychosis, using ¹H-MRS. Previous research has demonstrated that the hippocampus is a key substrate for pathophysiological alterations in psychosis (Allen et al., 2016; Cao and Cannon, 2020; Lieberman et al., 2018; Lodge and Grace, 2011; McHugo et al., 2019; Schobel et al., 2013; Vargas et al., 2018). Independent evidence also suggests that cellular neuropathology may be evident in the left rather than right hippocampus in schizophrenia (Roeske et al., 2020). As such, previous magnetic resonance spectroscopy (MRS) studies have commonly acquired data from the left hippocampus (Bossong et al., 2019; Briend et al., 2020; Merritt et al., 2016; Shakory et al., 2018). Therefore, for the present study, we investigated hippocampal glutamate levels of the left hippocampus. We predicted that administration of a single dose of CBD would be associated with an increase in left hippocampal glutamate levels and reduction in symptoms of psychosis. A secondary objective was to explore the relationship between left hippocampal glutamate levels and CBD effect on symptoms.

Methods

Participants

Informed consent was obtained from all participants, as approved by the National Research Ethics Service Committee London (Camberwell, St Giles, Ethics reference: 14/LO/1861).

Patients with psychosis in the early stages of illness (within 5 years of onset) were recruited from psychiatric services in the South London and Maudsley National Health Service (NHS) Foundation Trust, in London, UK. Seventeen patients were initially recruited to the study, 15 of whom attended both study days – one patient did not meet the study inclusion criteria while another withdrew consent. Psychosis diagnosis was confirmed by an experienced research psychiatrist using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV (American Psychiatric Association (APA), 2000). Briefly, inclusion criteria were as follows: (a) diagnosis of psychotic mental illness (meeting criteria for schizophrenia, schizophreniform or brief psychotic disorder – but no other Axis I diagnoses) and (b) within 5 years of onset of illness. Additional inclusion criteria as well as exclusion criteria are described in the Supplementary Material section.

Study design

Patients were studied over two sessions in a double-blind, placebo-controlled, repeated-measures, within-subject-crossover design, with at least a one-week interval (mean=28.87 days, range=6–114 days) between scans to allow washout of CBD (>3 times the elimination half-life of CBD (Devinsky et al., 2014; Hawksworth and McArdle, 2004)). A randomization sequence was generated by a research pharmacist at the South London and Maudsley NHS foundation Trust, and was used by the pharmacist to allocate patients to one of the two orders of drug administration (placebo followed by CBD or CBD followed by placebo).

On each study day, patients had a light standardised breakfast. Patients were given a gelatin capsule containing either CBD 600 mg (approx. 99.9% pure, Δ9-THC-Pharm, Frankfurt, Germany), or a visually identical placebo (PLB) capsule containing flour 120 min after breakfast. Participants then underwent ¹H-MRS scanning 180 min after drug administration. Blood samples were obtained via intravenous cannulation in the non-dominant arm to assay CBD levels at three time points: 60 min before drug administration (T1), 60 min after drug administration (T2), and 270 min after administration (T3) (see Supplementary Material).

Psychopathology was rated in patients using the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987), administered 60 min before drug administration (T1; pre ¹H-MRS scan), and again 270 min after administration (T3; post ¹H-MRS scan). ¹H-MRS spectra were acquired 180 min after drug administration.

All participants were advised to avoid alcohol intake for 24 h and caffeine intake for 12 h before the study. Additionally, all participants were asked to avoid using any recreational drugs (apart from cannabis amongst the patient group) for two weeks before the study day. A urine sample was obtained from all participants on each study day to screen for use of amphetamines, barbiturates, benzodiazepines, cocaine, methamphetamine, morphine, methadone, phencyclidine, tricyclic antidepressants and Δ9-THC, using the Alere Drug Screen Urine Test Cup. Carbon monoxide breath levels were also measured in the patient group, using the Bedfont Smokerlyzer.

¹H-MRS data acquisition

¹H-MRS resting-state spectra (Point RESolved Spectroscopy (PRESS); echo time (TE)=30 ms; repetition time (TR)=3 s; 96 averages, additional details in Supplementary Material) were acquired in the left hippocampus, as previously described by Stone et al. (2010), on a GE SIGNA HDx 3.0T MR scanner system (GE Medical Systems, Milwaukee, Wisconsin). We employed the standard GE probe (proton brain examination) sequence, using a standardised chemically selective suppression (CHESS) water suppression routine. For each metabolite spectrum, unsuppressed water reference spectra (16 averages) were also acquired as part of the standard acquisition. Shimming and water suppression were optimised, with auto-prescan performed twice before each scan. Using standardised protocols, the hippocampal region of interest (20×20×15 mm; right-left, anterior-posterior, superior-inferior) was prescribed from the structural T1 scan (see Supplementary Material). T1 images were acquired using a whole-brain 3D sagittal ADNI GO sequence, with the following parameters: TR/TE=6.98/2.85 ms; flip angle=11°; 196×1.2 mm slices; voxel size 1.0×1.0×1.2 mm; 256×256 matrix.

¹H-MRS quantification

All spectra were analysed with LCModel version 6.3-1L (see example spectra in the Supplementary Material) (Provencher, 1993). Cramer-Rao minimum variance bounds (as reported by LCModel) were less than 20% for all peaks, thus no subjects were excluded from the analyses following quality control checks. Water-scaled glutamate (Glu) values were corrected for cerebral spinal fluid (CSF) content of the hippocampal region of interest (ROI) using the formula

M c o r r = M^{*} (W M + 1.21 G M + 1.55 C S F) / (W M + G M)

where M is the uncorrected metabolite value, and WM, GM and CSF are the white matter, grey matter and CSF fractions of the ROI, respectively (Egerton et al., 2014). The WM, GM and CSF fractions were determined for each subject from the structural T1 scans, and subsequently segmented into GM, WM and CSF using SPM8 (https://www.fil.ion.ucl.ac.uk/spm/software/spm8/). As exploratory measures, CSF-corrected water-scaled values for glycerophosphocholine (GPC), combined glutamate and glutamine (Glx), N-acetyl aspartate (NAA), and myoinositol (mI) were also collected. All CSF-corrected metabolite values are reported in arbitrary units. ¹H-MRS data quality is described in Supplementary Material.

Additional analyses

Effect of CBD treatment on hippocampal Glu levels and symptoms was assessed using the non-parametric repeated measures Sign test. The Sign test was used as it has fewer assumptions (appropriate given the modest sample size) than standard parametric tests and is thus more conservative. Linear regression analysis was carried out to examine the relationship between severity of symptoms of psychosis following treatment (as indexed by total PANSS score at T3) and hippocampal Glu concentration after controlling for the effect of baseline symptoms (total PANSS score at T1), treatment (CBD vs PLB) and interaction between treatment and hippocampal Glu. Exploratory analyses of the effect of CBD treatment on the additional metabolites were also performed using the non-parametric repeated measures Sign test. All analyses were carried out using the R Stats package (R Core Team, 2018).

Results

Demographics and behavioural findings

Socio-demographic and clinical data are shown in Table 1 (additional details, including cannabis use, in Supplementary Material). Symptom ratings at pre-treatment (T1), and change following drug administration, on each of the study days are shown in Table 2.

Table 1.

Participant socio-demographic information.

Characteristic	PSY (n=15)
Characteristic	Mean (SD)
Age in years	27.73 (4.61)
Gender (% male)	66.7
Handedness (% right)	86.7
Education in years	14.23 (2.75)
Antipsychotic medication (atypical/typical/none)	14/0/1^a
CPZ equivalent dose mg/day	225.071 (96.22)

PSY: psychotic; SD: standard deviation, CPZ: clozapine.

Patient was prescribed olanzapine, but was not taking it.

Table 2.

Symptom scores for psychosis (PSY) patients at baseline (T1) and post-drug (T3) for both study days.

Characteristic	PSY-PLB	PSY-CBD	Statistics
Characteristic	Mean (SD)
T1 PANSS positive symptoms	12.53 (5.62)	12.93 (5.72)	Z=0, p-value=0.5
T1 PANSS negative symptoms	12.4 (6.4)	12.47 (6.56)	Z=−0.28, p-value=0.39
T1 PANSS general symptoms	23.87 (8.6)	25.6 (8.83)	Z=−1.29, p-value=0.098
T1 PANSS total symptoms	48.8 (18.9)	51 (20)	Z=−1.069, p-value=0.14
T3 PANSS positive symptoms	11.67 (4.99)	10.73 (3.41)	Z=0.301, p-value=0.62
T3 PANSS negative symptoms	11.53 (6.058)	10.2 (3.052)	Z=1.15, p-value=0.87
T3 PANSS general symptoms	21.4 (8.1)	20.6 (6.16)	Z=1.39, p-value=0.92
T3 PANSS total symptoms	44.6 (18.07)	41.53 (11)	Z=0.904, p-value=0.82
Change PANSS positive symptoms (T1–T3)	0.87 (2.2)	2.2 (4.11)	Z=−0.83, p-value=0.2
Change PANSS negative symptoms (T1–T3)	0.87 (2.82)	2.27 (4.17)	Z=−1.508, p-value=0.066
Change PANSS general symptoms (T1–T3)	2.47 (3.46)	5 (6.45)	Z=−1.6, p-value=0.054
Change PANSS total symptoms (T1–T3)	4.2 (7.61)	9.47 (14.17)	Z=−2.14, p-value=0.016

PANSS: Positive And Negative Syndrome Scale.

PSY-CBD refers to patients under cannabidiol condition; PSY-PLB refers to patients under placebo condition; T1 is the time-point at 60 min before drug administration; T3 is the time-point at 270 min after drug administration. Significant differences are indicated in bold.

On the PLB treatment day, one patient was missing five T1 general PANSS item scores; one patient was missing one T3 positive PANSS score; and one patient was missing two T3 negative PANSS scores. On the CBD treatment day, one patient was missing seven T3 negative PANSS item scores. In these cases, the last observation carried forward method was used to impute the data – wherein a participant’s last observed score on the dependent variable is used for all subsequent (i.e. missing) observation points.

Symptoms at baseline (T1, pre-treatment) on each study day, as indexed by PANSS total scores were not significantly different between the CBD (PSY-CBD) and PLB (PSY-PLB) conditions (z=−1.069, one-tailed p=0.14). Across both treatment conditions, severity of psychosis symptoms as indexed by PANSS total scores improved following drug treatment, compared to baseline. This improvement was significantly greater under the CBD treatment condition than under the PLB treatment condition (z=−2.14; p=0.016) (Table 2, Figure 1).

Figure 1.

Change in total Positive and Negative Syndrome Scale (PANSS) scores pre- and post-treatment on the placebo and cannabidiol treatment days. Error bars=±1 standard deviation (SD).

Differences in glutamate levels across the groups

As predicted, there was a significant increase in left hippocampal glutamate levels under the CBD treatment condition (8.27±1.023) compared to the PLB treatment condition (7.84±0.9) (z=−1.80; one-tailed p=0.035) (Table 3, Figure 2).

Table 3.

Metabolite levels for psychosis (PSY) patients under placebo (PLB)/cannabidiol (CBD) conditions.

Metabolite	PSY-PLB	PSY-CBD	Statistics	Cohen’s d
Metabolite	Mean (SD)		Statistics	Cohen’s d
Glutamate	7.84 (0.9)	8.27 (1.023)	PSY-PLB vs PSY-CBD: p=0.035	PSY-PLB vs PSY-CBD: 0.48
Glutamate+glutamine	11 (1.92)	11.46 (1.19)	PSY-PLB vs PSY-CBD: p=0.79	PSY-PLB vs PSY-CBD: 0.24
Myoinositol	6.27 (1.064)	6.41 (1.11)	PSY-PLB vs PSY-CBD: p=0.79	PSY-PLB vs PSY-CBD: 0.13
N-acetyl aspartate	9.17 (1.18)	9.37 (1.26)	PSY-PLB vs PSY-CBD: p=0.79	PSY-PLB vs PSY-CBD: 0.17
Glycerophosphocholine	2.41 (0.28)	2.37 (0.29)	PSY-PLB vs PSY-CBD: p=0.59	PSY-PLB vs PSY-CBD: 0.14

SD: standard deviation.

PSY-CBD refers to patients under cannabidiol condition; PSY-PLB: refers to patients under placebo condition. Significant differences are indicated in bold.

Figure 2.

Cannabidiol (CBD)-related difference in left hippocampal glutamate levels, within individuals with psychosis. Hippocampal glutamate is presented as data corrected for voxel cerebrospinal fluid content, in arbitrary units (AU).

Differences in additional metabolite levels across the groups

No significant differences were observed between the PLB and CBD conditions, for any of the additional metabolites (Table 3).

Relationship between hippocampal glutamate and psychosis symptoms

There was a significant negative relationship between post-treatment (T3) total PANSS score and hippocampal Glu concentration (p=0.047), even after controlling for the effect of baseline symptoms (total PANSS score at T1), treatment (CBD vs PLB), and interaction between treatment and hippocampal Glu levels (Table 4, Figure 3).

Table 4.

Regression model showing the effect of hippocampal glutamate (Glu) on total Positive and Negative Syndrome Scale (PANSS) score post-treatment.

Predictor	Estimate	Std error	t value	p value
T1 PANSS total symptoms	0.61	20.37	2.709	<0.001
Group (CBD)	−23.26	26.75	−0.87	0.39
Hippocampal Glu	−5.17	2.48	−2.083	0.047
Group (CBD): Hippocampal Glu	2.54	3.31	0.77	0.45

CBD: cannabidiol.

Results of the linear regression analysis examining the relationship between severity of total PANSS symptoms following treatment (as indexed by total PANSS score at T3) and hippocampal Glu concentration, after controlling for the effect of baseline symptoms (total PANSS score at T1), treatment (CBD vs placebo), and interaction between treatment and hippocampal Glu. Adjusted R²=0.68. Significant differences are indicated in bold.

Figure 3.

Significant negative relationship between hippocampal glutamate and Positive and Negative Syndrome Scale (PANSS) total score post treatment (p=0.047), controlling for the effect of baseline symptoms (total PANSS score at T1), treatment (cannabidiol (CBD) vs placebo (PLB)), and interaction between treatment and hippocampal glutamate levels.

Discussion

In this study, as predicted, a single dose of CBD given to patients with psychosis significantly increased hippocampal glutamate levels. This was accompanied by a significantly greater reduction in symptoms of psychosis, as indexed by total PANSS score, under CBD compared to PLB treatment. Furthermore, there was a significant inverse relationship between hippocampal glutamate levels and severity of psychosis symptoms post-treatment, even after controlling for baseline symptom severity and treatment. However, this relationship did not seem to be significantly different under CBD compared to PLB treatment.

Overall, these findings may suggest an inverse relationship between hippocampal glutamate levels and symptoms of psychosis. As there was an increase in glutamate levels and a concomitant acute decrease in symptom severity under CBD, this may also suggest that the acute improvement in symptoms of psychosis under CBD may be linked to the increase in hippocampal glutamate concentration, as indexed by ¹H-MRS, under its influence. However, this should be interpreted with caution, as the correlation between hippocampal glutamate and symptoms was not selective for CBD exposure. Previous studies linking glutamate levels to symptoms in patients with psychotic disorder have been inconsistent, as reviewed by Merritt et al. (2013). However, administration of NMDA receptor antagonists has been shown to induce the full spectrum of psychotic symptoms in healthy individuals (Javitt, 2007; Newcomer et al., 1999), and worsen positive, negative and cognitive symptoms in patients with psychosis (Lahti et al., 1995; Malhotra et al., 1997). The direction of the CBD-induced change in glutamate level observed in the current study is in keeping with recent clinical and preclinical evidence (Linge et al., 2016; Pretzsch et al., 2019). It is also consistent with previous studies reporting lower levels of glutamate in more chronic compared to un-medicated patients or those in earlier stages of illness (Schwerk et al., 2014).

As noted earlier, traditional drugs for psychosis typically target the dopaminergic neurotransmitter system, varying in efficacy in the treatment of positive symptoms, and providing only modest benefit in the treatment of the negative and cognitive symptoms of psychosis (Beck et al., 2016). In contrast, glutamatergic models of psychosis may provide more inclusive explanations for the psychotic symptoms and cognitive impairments observed in the disorder, with hypofunction of the NMDA receptors being a prominent pathophysiological feature (Coyle, 1996; Li and Tsien, 2009; Newcomer et al., 1999). Such models are supported by the psychotomimetic effects of NMDA receptor antagonists in healthy individuals (Javitt, 2007; Newcomer et al., 1999); and by the discovery of abnormal markers of NMDA receptor neurotransmission in post-mortem brains (Beneyto et al., 2007; Kristiansen et al., 2006), and abnormal levels of glutamatergic metabolites throughout the brain in vivo (Bartha et al., 1997; Bustillo et al., 2017; Tayoshi et al., 2009), in patients with psychosis. The ubiquitous distribution of glutamate receptors throughout the brain, and the crucial role of NMDA receptors specifically in the modulation of synaptic plasticity, further implicate the disruption of these receptors in widespread dysfunction (Howes et al., 2015; Li and Tsien, 2009). However, clinical trials of glutamatergic drugs for psychosis have been largely unsuccessful (Beck et al., 2016). Although the current findings are promising in terms of suggesting a potential glutamatergic mechanism for candidate drugs for psychosis, previous experience with glutamatergic treatments indicate that there is a particular need for caution, pending independent replication. Further studies involving sustained treatment with CBD are also needed, particularly exploring the relationship between change in pre-treatment glutamate levels and the effect of CBD on symptoms as well as cognitive impairments in psychosis.

The molecular mechanisms that may underlie the effect of CBD on glutamate levels in patients are unclear as are the molecular mechanisms that may underlie its antipsychotic effects. A range of mechanisms have been suggested as potentially operative either individually or in conjunction with others to produce the antipsychotic and anxiolytic effects of CBD (Leweke et al., 2012; Mechoulam et al., 2007). Some of these include the inhibition of adenosine reuptake (Carrier et al., 2006), agonism of the transient potential vanilloid-1 (TRPV-1) and serotonergic 5-HT1A receptors (Bisogno et al., 2001; Russo et al., 2005), and partial agonism of the dopamine D2High receptor (Seeman, 2016). Agonism of the pre-synaptic TRPV-1 receptor in particular can also facilitate glutamate release (Xing and Li, 2007). Another prominent potential mechanism involves the endocannabinoid system. It is thought to play a critical role in regulating glutamatergic signalling, modulating NMDA receptor activity in order to prevent excitotoxicity (Sanchez-Blazquez et al., 2014). The endocannabinoid system has also been strongly implicated in the pathophysiology of psychosis in both clinical and pre-clinical studies (Appiah-Kusi et al., 2016; Bhattacharyya et al., 2012b; Bossong et al., 2014; Dalton et al., 2011; D’Souza et al., 2004; Leweke et al., 2016; Muguruza et al., 2013). It follows that aberrant activity of the endocannabinoid system resulting in NMDA receptor hypofunction could support the glutamatergic model of psychosis (Sanchez-Blazquez et al., 2014). Furthermore, CBD has been shown to disrupt the action of agonists of the cannabinoid 1 (CB1) receptor, the primary endocannabinoid receptor. In this way, CBD-induced modulation of hippocampal glutamate levels and concomitant improvement in psychotic symptoms may suggest that an effect on hippocampal endocannabinoid tone could underlie the antipsychotic effects of CBD. Whatever the mechanism is that ultimately underlies the effect of CBD on hippocampal glutamate, it is important to note that this process and outcome may not reflect the effect in other brain regions, given the findings of previous clinical and pre-clinical studies (Gobira et al., 2015; Linge et al., 2016; Pretzsch et al., 2019), as well as their relationship with symptomatic effects.

The main limitation of this study was its relatively modest sample size. We attempted to mitigate this by employing a within-subject repeated measures design, allowing each participant to act as their own control. This helped minimise the effect of between-subject differences such as concomitant antipsychotic medications and comorbid drug use. Nevertheless, we cannot completely rule out that some of the changes in hippocampal glutamate observed in the present study were related to concomitant treatment with antipsychotic medication. However, further studies are needed to confirm these findings in larger samples of patients, and to examine whether these effects persist after a sustained period of treatment. Another limitation worth considering relates to the potential confounding of the current results by the carry-over effects of CBD in participants who received it on their first study session. While we aimed to limit this by using a counter-balanced order of administration, ultimately, we had 15 patients who completed the study, with seven receiving PLB first, and eight receiving CBD first. However, our between-session interval was substantially over the typical recommended threshold of three times the elimination half-life of CBD (Devinsky et al., 2014), making it unlikely that any carry-over effects of CBD would have persisted by the second study session. Furthermore, post-hoc analyses revealed no significant differences in change in glutamate levels (CBD minus PLB condition) between those who received PLB first, compared to those who received CBD first (data not shown here). Nevertheless, we cannot completely rule out this possibility.

In conclusion, we identified that a single dose of CBD modulated hippocampal glutamate levels and symptoms of psychosis, in patients with established psychosis. These findings are in keeping with the purported antipsychotic effects of CBD in psychosis, and provide novel insight into potential neurochemical mechanisms underlying these effects.

Supplemental Material

sj-docx-1-jop-10.1177_02698811211001107 – Supplemental material for Cannabidiol modulation of hippocampal glutamate in early psychosis

Supplemental material, sj-docx-1-jop-10.1177_02698811211001107 for Cannabidiol modulation of hippocampal glutamate in early psychosis by Aisling O’Neill, Luciano Annibale, Grace Blest-Hopley, Robin Wilson, Vincent Giampietro and Sagnik Bhattacharyya in Journal of Psychopharmacology

Footnotes

Acknowledgements

The following author contributions were made: AO’N and SB contributed to the conception of the work, interpretation of the data, and final approval of the version to be published. AO’N, RW and GB-H contributed to the acquisition of the data. AO’N, LA and SB contributed to the analysis of the work. AO’N, VG and SB contributed to the drafting and revising of the work.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by grants from the Medical Research Council (MRC), UK (MR/J012149/1 and MC_PC_14105 v.2 to SB) and also by support from the National Institute for Health Research (NIHR) (NIHR Clinician Scientist Award; NIHR CS-11-001) and from the NIHR Mental Health Biomedical Research Centre at South London and Maudsley National Health Service (NHS) Foundation Trust and King’s College London (both to SB). AO’N was supported by the NIHR Collaboration for Leadership in Applied Health Research and Care South London, at King’s College Hospital NHS Foundation Trust.

ORCID iD

Aisling O’Neill

References

Allen

Chaddock

Egerton

, et al. (2016) Resting hyperperfusion of the hippocampus, midbrain, and basal ganglia in people at high risk for psychosis. Am J Psychiatry 173: 392–399.

American Psychiatric Association (APA) (2000) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: APA.

Appiah-Kusi

Leyden

Parmar

, et al. (2016) Abnormalities in neuroendocrine stress response in psychosis: The role of endocannabinoids. Psychol Med 46: 27–45.

Bartha

Williamson

Drost

, et al. (1997) Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 54: 959–965.

Beck

Javitt

Howes

(2016) Targeting glutamate to treat schizophrenia: Lessons from recent clinical studies. Psychopharmacology (Berl) 233: 2425–2428.

Beneyto

Kristiansen

Oni-Orisan

, et al. (2007) Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 32: 1888–1902.

Bhattacharyya

Atakan

Martin-Santos

, et al. (2012a) Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of delta-9-tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry 17: 1152–1155.

Bhattacharyya

Crippa

Allen

, et al. (2012b) Induction of psychosis by ∆9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry 69: 27–36.

Bhattacharyya

Falkenberg

Martin-Santos

, et al. (2015) Cannabinoid modulation of functional connectivity within regions processing attentional salience. Neuropsychopharmacology 40: 1343–1352.

10.

Bhattacharyya

Fusar-Poli

Borgwardt

, et al. (2009) Modulation of mediotemporal and ventrostriatal function in humans by ∆9-tetrahydrocannabinol: A neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 66: 442–451.

11.

Bhattacharyya

Morrison

Fusar-Poli

, et al. (2010) Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35: 764–774.

12.

Bhattacharyya

Wilson

Appiah-Kusi

, et al. (2018) Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: A randomized clinical trial. JAMA Psychiatry 75: 1107–1117

13.

Bisogno

Hanus

De Petrocellis

, et al. (2001) Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845–852.

14.

Boggs

Surti

Gupta

, et al. (2018) The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology (Berl) 235: 1923–1932.

15.

Bossong

Antoniades

Azis

, et al. (2019) Association of hippocampal glutamate levels with adverse outcomes in individuals at clinical high risk for psychosis. JAMA Psychiatry 76: 199–207.

16.

Bossong

Jager

Van Hell

, et al. (2012) Effects of ∆9-tetrahydrocannabinol administration on human encoding and recall memory function: A pharmacological FMRI study. J Cogn Neurosci 24: 588–599.

17.

Bossong

Jansma

Bhattacharyya

, et al. (2014) Role of the endocannabinoid system in brain functions relevant for schizophrenia: An overview of human challenge studies with cannabis or 9-tetrahydrocannabinol (THC). Prog Neuropsychopharmacol Biol Psychiatry 52: 53–69.

18.

Brandt

Unschuld

Pradhan

, et al. (2016) Age-related changes in anterior cingulate cortex glutamate in schizophrenia: A (1)H MRS Study at 7 Tesla. Schizophr Res 172: 101–105.

19.

Briend

Nelson

Maximo

, et al. (2020) Hippocampal glutamate and hippocampus subfield volumes in antipsychotic-naive first episode psychosis subjects and relationships to duration of untreated psychosis. Transl Psychiatry 10: 137.

20.

Bustillo

Jones

Chen

, et al. (2017) Glutamatergic and neuronal dysfunction in gray and white matter: A spectroscopic imaging study in a large schizophrenia sample. Schizophr Bull 43: 611–619.

21.

Campos

Fogaça

Sonego

, et al. (2016) Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res 112: 119–127.

22.

Cao

Cannon

(2020) New evidence supporting a role of hippocampus in the development of psychosis. Biol Psychiatry 87: 200–201.

23.

Carrier

Auchampach

Hillard

(2006) Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A 103: 7895–7900.

24.

Coyle

(1996) The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 3: 241–253.

25.

D’Souza

Abi-Saab

Madonick

, et al. (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol Psychiatry 57: 594–608.

26.

D’Souza

Perry

Macdougall

, et al. (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology 29: 1558–1572.

27.

Dalton

Long

Weickert

, et al. (2011) Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology 36: 1620–1630.

28.

Devinsky

Cilio

Cross

, et al. (2014) Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55: 791–802.

29.

Duarte

JMN

Xin

(2019) Magnetic resonance spectroscopy in schizophrenia: Evidence for glutamatergic dysfunction and impaired energy metabolism. Neurochem Res 44: 102–116.

30.

Egerton

Stone

Chaddock

, et al. (2014) Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis. Neuropsychopharmacology 39: 2891–2899.

31.

Englund

Morrison

Nottage

, et al. (2013) Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 27: 19–27.

32.

Gobira

Vilela

Goncalves

, et al. (2015) Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: Possible role of the mTOR pathway and reduction in glutamate release. Neurotoxicology 50: 116–121.

33.

Gomes

Issy

Ferreira

, et al. (2014) Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice. Int J Neuropsychopharmacol 18: pyu041.

34.

Hashimoto

Engberg

Shimizu

, et al. (2005) Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry 5: 6.

35.

Hawksworth

McArdle

(2004) Metabolism and Pharmacokinetics of Cannabinoids. London: Pharmaceutical Press.

36.

Howes

McCutcheon

Stone

(2015) Glutamate and dopamine in schizophrenia: An update for the 21st century. J Psychopharmacol 29: 97–115.

37.

Iwata

Nakajima

Plitman

, et al. (2018) Neurometabolite levels in antipsychotic-naive/free patients with schizophrenia: A systematic review and meta-analysis of (1)H-MRS studies. Prog Neuropsychopharmacol Biol Psychiatry 86: 340–352.

38.

Jauhar

McCutcheon

Borgan

, et al. (2018) The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: A cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study. Lancet Psychiatry 5: 816–823.

39.

Javitt

(2007) Glutamate and schizophrenia: Phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78: 69–108.

40.

Kay

Fiszbein

Opler

(1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261–276.

41.

Kristiansen

Beneyto

Haroutunian

, et al. (2006) Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol Psychiatry 11: 737–747, 705.

42.

Lahti

Koffel

Laporte

, et al. (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13: 9–19.

43.

Leweke

Mueller

Lange

, et al. (2016) Therapeutic potential of cannabinoids in psychosis. Biol Psychiatry 79: 604–612.

44.

Leweke

Piomelli

Pahlisch

, et al. (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2: e94.

45.

Tsien

(2009) Memory and the NMDA receptors. N Engl J Med 361: 302–303.

46.

Lieberman

Girgis

Brucato

, et al. (2018) Hippocampal dysfunction in the pathophysiology of schizophrenia: A selective review and hypothesis for early detection and intervention. Mol Psychiatry 23: 1764–1772.

47.

Linge

Jimenez-Sanchez

Campa

, et al. (2016) Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: Role of 5-HT1A receptors. Neuropharmacology 103: 16–26.

48.

Lodge

Grace

(2011) Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol Sci 32: 507–513.

49.

Long

Malone

Taylor

(2006) Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 31: 795–803.

50.

Malhotra

Pinals

Adler

, et al. (1997) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17: 141–150.

51.

McGuire

Robson

Cubala

, et al. (2017) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. Am J Psychiatry. Epub ahead of print 15 December 2017. DOI: 10.1176/appi.ajp.2017.17030325.

52.

McHugo

Talati

Armstrong

, et al. (2019) Hyperactivity and reduced activation of anterior hippocampus in early psychosis. Am J Psychiatry 176: 1030–1038.

53.

Marsman

Van Den Heuvel

Klomp

, et al. (2013) Glutamate in schizophrenia: A focused review and meta-analysis of (1)H-MRS studies. Schizophr Bull 39: 120–129.

54.

Mechoulam

Peters

Murillo-Rodriguez

, et al. (2007) Cannabidiol–recent advances. Chem Biodivers 4: 1678–1692.

55.

Merritt

Egerton

Kempton

, et al. (2016) Nature of glutamate alterations in schizophrenia: A meta-analysis of proton magnetic resonance spectroscopy studies. JAMA Psychiatry 73: 665–674.

56.

Merritt

McGuire

Egerton

(2013) Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis. Front Psychiatry 4: 151.

57.

Moore

Zammit

Lingford-Hughes

, et al. (2007) Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 370: 319–328.

58.

Moreira

Guimarães

(2005) Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 512: 199–205.

59.

Morgan

Schafer

Freeman

, et al. (2010) Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: Naturalistic study: Naturalistic study [corrected]. Br J Psychiatry 197: 285–290.

60.

Muguruza

Lehtonen

Aaltonen

, et al. (2013) Quantification of endocannabinoids in postmortem brain of schizophrenic subjects. Schizophr Res 148: 145–150.

61.

Newcomer

Farber

Jevtovic-Todorovic

, et al. (1999) Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20: 106–118.

62.

Ohrmann

Siegmund

Suslow

, et al. (2005) Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: A proton magnetic resonance spectroscopy study. Schizophr Res 73: 153–157.

63.

O’Neill

Wilson

Blest-Hopley

, et al. (2020) Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis. Psychol Med. Epub ahead of print 29 January 2020. DOI: 10.1017/S0033291719003519.

64.

Pretzsch

Freyberg

Voinescu

, et al. (2019) Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology 44: 1398–1405.

65.

Provencher

(1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30: 672–679.

66.

R Core Team (2018) R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing.

67.

Ranganathan

Radhakrishnan

Addy

, et al. (2017) Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information. Prog Neuropsychopharmacol Biol Psychiatry 79: 176–183.

68.

Roeske

Konradi

Heckers

, et al. (2020) Hippocampal volume and hippocampal neuron density, number and size in schizophrenia: A systematic review and meta-analysis of postmortem studies. Mol Psychiatry. Epub ahead of print 28 July 2020. DOI: 10.1038/s41380-020-0853-y.

69.

Russo

Burnett

Hall

, et al. (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30: 1037–1043.

70.

Sanchez-Blazquez

Rodriguez-Munoz

Garzon

(2014) The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: Implications in psychosis and schizophrenia. Front Pharmacol 4: 169.

71.

Schobel

Chaudhury

Khan

, et al. (2013) Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron 78: 81–93.

72.

Schoeler

Bhattacharyya

(2013) The effect of cannabis use on memory function: An update. Subst Abuse Rehabil 4: 11–27.

73.

Schoeler

Monk

Sami

, et al. (2016a) Continued versus discontinued cannabis use in patients with psychosis: A systematic review and meta-analysis. Lancet Psychiatry 3: 215–225.

74.

Schoeler

Petros

Di Forti

, et al. (2016b) Association between continued cannabis use and risk of relapse in first-episode psychosis: A quasi-experimental investigation within an observational study. JAMA Psychiatry 73: 1173–1179.

75.

Schwerk

Alves

Pouwels

, et al. (2014) Metabolic alterations associated with schizophrenia: A critical evaluation of proton magnetic resonance spectroscopy studies. J Neurochem 128: 1–87.

76.

Seeman

(2016) Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Transl Psychiatry 6: e920.

77.

Shakory

Watts

Hafizi

, et al. (2018) Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis. Neuropsychopharmacology 43: 2249–2255.

78.

Stone

Howes

Egerton

, et al. (2010) Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol Psychiatry 68: 599–602.

79.

Tayoshi

Sumitani

Taniguchi

, et al. (2009) Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr Res 108: 69–77.

80.

Tibbo

Hanstock

Valiakalayil

, et al. (2004) 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry 161: 1116–1118.

81.

Vargas

Dean

Osborne

, et al. (2018) Hippocampal subregions across the psychosis spectrum. Schizophr Bull 44: 1091–1099.

82.

Winton-Brown

Allen

Bhattacharyya

, et al. (2011) Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: An FMRI study. Neuropsychopharmacology 36: 1340–1348.

83.

Xing

(2007) TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons. J Neurophysiol 97: 503–511.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.62 MB

Cannabidiol modulation of hippocampal glutamate in early psychosis

Abstract

Background:

Aim:

Methods:

Results:

Conclusions:

Keywords

Introduction

Methods

Participants

Study design

1H-MRS data acquisition

1H-MRS quantification

Additional analyses

Results

Demographics and behavioural findings

Differences in glutamate levels across the groups

Differences in additional metabolite levels across the groups

Relationship between hippocampal glutamate and psychosis symptoms

Discussion

Supplemental Material

sj-docx-1-jop-10.1177_02698811211001107 – Supplemental material for Cannabidiol modulation of hippocampal glutamate in early psychosis

Footnotes

Acknowledgements

Declaration of conflicting interests

Funding

ORCID iD

References

Supplementary Material

¹H-MRS data acquisition

¹H-MRS quantification